Nasopharyngeal carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
A tumor suppressor gene p53 is mostly intact and overexpressed in NPC whereas expression of p16, a cyclin-dependent kinase inhibitory protein, is downregulated in 2/3 of NPC.
|
21592702 |
2012 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Widespread apoptosis was detected after treatment for 2-6 days in C15 as well as two other NPC xenografts, C17 and C18; the latter NPCs have mutations in the p53 gene.
|
9458076 |
1998 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that alterations of the p53 gene are unlikely to be involved in the initial genetic events leading to the clonal outgrowth in NPC.
|
1349927 |
1992 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The p53 gene mutations are infrequently found in NPC, but the expression of p53 protein, as well as bcl-2 oncoprotein, has been reported in a high percentage of cases, and also in association with EBV.
|
11053650 |
2000 |
Nasopharyngeal carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
To determine the role of p53 in NPC, we screened for p53 mutations and evaluated the protein expression levels in samples from local patients with NPC.
|
19900105 |
2009 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Special caution should be taken with patients with cancers such as nasopharyngeal carcinoma in which p53 mutation is infrequent and radiotherapy is the main choice of treatment.
|
10029407 |
1999 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to assess possible associations of NPC risk with TP53 codon 72 polymorphisms.
|
19608020 |
2009 |
Nasopharyngeal carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical studies have shown significant p53 overexpression in NPC material.
|
15523893 |
2005 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, p53 mutation is frequently observed in cell lines derived from the primary NPC tumors.
|
1295443 |
1993 |
Nasopharyngeal carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Data also suggested that cellular miR-34b, miR-34c, miR-18a, miR‑200a/b, miR-449a, miR-31 and let-7 may be dysregulated in NPCs, and that the aberrant activation of their target genes in the p53 pathway and cell cycle enhance NPC cell survival and proliferation.
|
26330189 |
2015 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia.
|
17954263 |
2007 |
Nasopharyngeal carcinoma
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Nasopharyngeal carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
High levels of recombinant p53 protein expression were also observed in the NPC cell lines when treated with Ad5CMV-p53 at 50 pfu/cell.
|
9815713 |
1997 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Collectively, we suggest that the p53 gene polymorphism may associate with NPC susceptibility in Thai population, particularly the Pro/Pro genotype carriers with age of >40 years.
|
12893432 |
2003 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Unlike in most human solid tumors, TP53 mutations are rare in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues, suggesting a possibility that some EBV-encoded products suppress the functions of p53.
|
30209170 |
2018 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
Nasopharyngeal carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
On the whole, these findings indicate that COX-2 may play a critical role in chemotherapeutic resistance in NPC via the inhibition of chemotherapy-induced senescence via the inactivation of p53.
|
29956730 |
2018 |
Nasopharyngeal carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutations in WAF-1/CIP-1/p21 might mimic p53 mutations in tumors having wild-type p53 such as most NPCs.
|
7606201 |
1995 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The findings suggest that polymorphisms of MDM2 and TP53 genes may be genetic modifier for developing NPC.
|
20398418 |
2010 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We concluded that there were the correlations between NPSCC subtypes with EBV infection and frequent intaking of pickled food, while aging, clinical recurrence, and TP53 gene mutations were independent predictors for the poor prognosis of nasopharyngeal carcinoma.
|
30964122 |
2019 |
Nasopharyngeal carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our data indicate that p53 is also an infrequent event among NPC patients at low risk for the disease.
|
9232335 |
1997 |
Nasopharyngeal carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis showed that the p53 codon 72 Pro/Pro genotype [hazard ratio (HR), 0.300; 95% confidence interval (CI), 0.092-0.983; P=0.047] and heavy smoking (≥30 pack-years) (HR, 2.899; 95% CI, 1.349-6.229; P=0.006) are independent significant prognostic factors for PFS in patients with locoregionally advanced NPC.
|
24173110 |
2014 |
Nasopharyngeal carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Seventy-three cases of NPC were investigated to examine the immunohistochemical expression of iNOS, 8-OHdG and latent membrane protein-1 (LMP-1) and Epstein-Barr virus-encoded small RNA (EBER) expression using in situ hybridization. iNOS mRNA expression and p53 gene mutations were also assessed.
|
18184270 |
2008 |
Nasopharyngeal carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Alternative mechanisms of p53 inactivation in NPC are also possible.
|
7729941 |
1995 |
Nasopharyngeal carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings suggest that NOLC1 plays a role in the regulation of tumorigenesis of NPC and demonstrate that both NOLC1 and tumor protein 53 work together synergistically to activate the MDM2 promoter in NPC cells.
|
19541936 |
2009 |